[ 메디채널 황정호 기자 ] マスカット(オマーン), 2025年12月8日 -- ロンドン証券取引所上場の高級不動産開発会社であるDar Global(LSE: DAR)は、Art District Real Estate Developmentとの提携により、本日、マスカット海洋、芸術、デジタル地区「MAD」の立ち上げと開発に向けた協業開始を発表しました。これは、海辺の生活、高級ホスピタリティ、文化主導型企業、未来志向の金融・デジタル産業を統合した革新的な新たな沿岸地域です。 オマーンの美しい海岸線に沿って位置する「MAD」プロジェクトは、総開発面積150万平方メートル以上、全開発フェーズにおける総開発価値は約16億オマーン・リアル(42億米ドル)に上り、12年以上にわたる開発計画となります。海を望む居住空間、ラグジュアリーホスピタリティ、文化的表現、そして未来の金融・デジタル産業を統合した単一のエコシステムを構築することで、オマーン・スルタン国の国際的地位向上を目指します。 複合型都市として構想された「MAD」は、高級住宅コミュニティ、文化施設、世界水準のマリーナ、厳選された小売店舗、次世代金融・ビジネスパーク、プレミアムホテルを集結させます。この地区は、富裕層旅行者、グローバル投資家、アートコレクター、テック起業家、クリエ
SAN FRANCISCO, Dec. 9, 2025 -- From December 7 to 8, Kweichow Moutai celebrated a dual milestone - the 110th anniversary of its award-winning debut at the 1915 Panama-Pacific International Exposition and the 10th anniversary of San Francisco Moutai Day - through a dynamic series of events that captivated local attendees. By blending an immersive cultural exhibition with the elegant "Moutai Night" gala dinner, the celebration offered guests a multifaceted experience rich in history, culture, and curated tastings. The events drew leaders from political, business, and cu
[ 메디채널 김장윤(JASON KIM) 기자 ] 台北、2025年12月9日 -- 世界有数のコンピューター・ブランドであるGIGABYTEは、AORUS PRIME 5が正式に発売されたことを発表しました。この高性能デスクトップ・システムは、フラッグシップ グレードのハードウェアと、GIGABYTE独自の冷却技術革新および高度なファン・テクノロジーを組み合わせた新しいアーキテクチャに基づいて構築されています。AORUS PRIME 5は、ゲームやマルチタスクに優れた速度と長期的な信頼性を提供するように設計されており、パワー、精度、デザインをシンプルなプラグ・アンド・プレイと融合しています。 AORUS PRIME 5は、マルチコアと次世代AIパフォーマンスを実現するAMD Ryzen™ 7 9800X3DプロセッサとNVIDIA® GeForce RTX™ 5080グラフィック・カードを搭載可能。さらに、2TB SSDと32GBの高速RGBメモリを含むGIGABYTE製品のみで構築された設計により、超高速の応答性とシームレスなマルチタスクを実現します。この構成は、実証済みの安定性というGIGABYTE のDNAを体現しており、その優れた性能は、完全に統合された冷却ソリューションにも反映されています。 新しいHawk F
SUZHOU, China, Dec. 8, 2025 -- Convergen, a biotech company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today announced the closing of a $10 million Seed financing round. The round was invested by Qiming Venture Partners, a leading global venture capital firm focused on life sciences and healthcare innovation. Funds from the financing will accelerate the development of Convergen's proprietary TrimTAC platform—next-generation bifunctional degraders leveraging the E3 ubiquitin ligase TRIM21—and advance its early
– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement –– Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes –– Favorable safety profile with no treatment-related serious adverse events – LEHI, Utah, Dec. 8, 2025 -- Halia Therapeutics, a clinical-stage biopharmaceutical company, today presented new clinical data from its Phase 2a study of ofirnoflast (HT-6184) at the 67th American Society of Hematology (ASH) Annual Meeting. The data show that ofirnoflast, a first-
DUBAI, UAE, Dec. 8, 2025 -- AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C, (the "Company") (Nasdaq: AHMA), a United Arabic Emirates-based MICE (meetings, incentives, conferences, and exhibitions) and tourism services provider, today announced its unaudited financial results for the six months ended June 30, 2025. Financial Highlights for the Six Months Ended June 30, 2025 Revenue increased by 14% to US$9.7 million for the six months ended June 30, 2025, from US$8.5 million for the six months ended June 30, 2024. MICE management solution services revenue increased by 3
SINGAPORE, Dec. 8, 2025 -- ALR Technologies SG Ltd ("ALRT" or the "Company") (OTC: ALRTF), the diabetes management company, announces the successful completion of internal manufacturing testing on the GluCurve Pet CGM ("GluCurve") showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026. GluCurve is the first and only diabetic monitoring system built specifically for veterinary use on cats and dogs. A pet-friendly Continuous Glucose Monitor
INCHEON, South Korea, Dec. 8, 2025 -- Zymedi (CEO Sunghoon Kim) announced that the World Health Organization (WHO) has assigned rapaprutug as the International Nonproprietary Name (INN) for the company's first-in-class antibody therapy ZMA001, being developed as a treatment for pulmonary arterial hypertension (PAH). The assignment of the name rapaprutug (development code: ZMA001) marks a key global milestone and establishes a unified scientific identity for Zymedi's lead candidate as it advances through development. The antibody is currently being evaluated in an ongoing Phase 1 clinic
Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programs SEOUL, South Korea, Dec. 8, 2025 -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for Lunit INSIGHT Risk, a mammography-based five-year breast cancer risk prediction model. Potential clearance is expected in 2026. Lunit INSIGHT Risk estimates a woman's five-year bre
NEW YORK, Dec. 8, 2025 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + ICE Data Show Home Affordability at Nearly Three-Year High Kristen Scholer delivers the pre-market update on December 8th Wall Street awaits the final interest rate decision of the year, with the Fed widely expected to cut borrowing costs by 0.25 percentage points on Wednesday at 2:00 PM ET, followed